Blog

FDA Gives Approval for New Class of Medications to Treat Type 2 Diabetes in Pediatric Patients

FDA Gives Approval for New Class of Medications to Treat Type 2 Diabetes in Pediatric Patients

The U.S. Food and Drug Administration (FDA) has approved two medications, Jardiance and Synjardy, as treatment options for children aged 10 and older with type 2 diabetes. This is significant, as children with type 2 diabetes have limited treatment options compared to adults. Type 2 diabetes is a chronic condition where the body does not […]

Continue Reading

FDA Issues Over 180 Warning Letters to Retailers Selling Youth-Appealing Elf Bar and Esco Bars E-Cigarettes in Wake of Inspection Blitz

FDA Issues Over 180 Warning Letters to Retailers Selling Youth-Appealing Elf Bar and Esco Bars E-Cigarettes in Wake of Inspection Blitz

The U.S. Food and Drug Administration (FDA) has issued warning letters to 189 retailers for selling unauthorized tobacco products, specifically Elf Bar and Esco Bars products. Both brands are disposable e-cigarettes that come in flavors known to appeal to youth, such as bubblegum and cotton candy. The FDA is committed to using all of its […]

Continue Reading

FDA Grants Traditional Approval for Novel Alzheimer’s Disease Treatment

FDA Grants Traditional Approval for Novel Alzheimer’s Disease Treatment

The U.S. Food and Drug Administration (FDA) has converted the drug Leqembi (lecanemab-irmb) from accelerated approval to traditional approval for the treatment of Alzheimer’s disease. This decision was made after a confirmatory trial showed that the drug provides clinical benefit. Leqembi is the first amyloid beta-directed antibody to receive traditional approval for Alzheimer’s disease. The […]

Continue Reading

FDA Grants Full Approval to Eisai’s Alzheimer’s Drug, but Issues Stronger Safety Alert

FDA Grants Full Approval to Eisai’s Alzheimer’s Drug, but Issues Stronger Safety Alert

Eisai, a Tokyo-based pharmaceutical company, has received full FDA approval for its Alzheimer’s disease drug, Leqembi. This decision not only marks a significant milestone for the treatment of Alzheimer’s but also sets a precedent for the review and potential approval of other therapies for the neurodegenerative disorder. Leqembi is an antibody that targets the buildup […]

Continue Reading

FDA Releases Initial Version of Guidelines for Clinical Trials Involving Psychedelic Drugs

FDA Releases Initial Version of Guidelines for Clinical Trials Involving Psychedelic Drugs

The U.S. Food and Drug Administration (FDA) has published a new draft guidance addressing the use of psychedelic drugs for potential medical treatment. This is the first FDA draft guidance that provides considerations to industry for designing clinical trials involving psychedelic drugs. Psychedelic drugs have gained interest for their therapeutic potential in recent years. They […]

Continue Reading

FDA’s Proposed Unified Human Foods Program Gets an Update: Introducing a Fresh Model for the Office of Regulatory Affairs

FDA’s Proposed Unified Human Foods Program Gets an Update: Introducing a Fresh Model for the Office of Regulatory Affairs

The U.S. Food and Drug Administration (FDA) has announced updates to its proposal for a unified Human Foods Program (HFP) and a new model for the Office of Regulatory Affairs (ORA). The changes aim to enhance coordination, prevention, and response activities across the FDA and improve the agency’s ability to support public health goals. The […]

Continue Reading

Latest FDA Updates: June 27, 2023

Latest FDA Updates: June 27, 2023

The U.S. Food and Drug Administration (FDA) has released several updates and guidance documents to improve food safety, drug development, orthopedic implants, and consumer-friendly labeling. One of the updates includes new frequently asked questions and tools for industry regarding the FDA Food Safety Modernization Act (FSMA) Food Traceability Rule. This rule aims to identify and […]

Continue Reading